ARVO to award young scientists
A series of awards granted to scientists under the age of 45 has been announced by the Association for Research in Vision and Ophthalmology (ARVO) Foundation for Eye Research (AFER) and Merck & Co, Inc.
A series of awards granted to scientists under the age of 45 has been announced by the Association for Research in Vision and Ophthalmology (ARVO) Foundation for Eye Research (AFER) and Merck & Co, Inc.
The ARVO-AFER/Merck Innovative Ophthalmology Research Award (IORA) grants, totalling $70,000 per cycle, will be awarded biennially to young scientists of MD, PhD or equivalent level throughout the world who have made "innovative contributions to ophthalmology research". The awards are granted in the categories of glaucoma and back-of-eye diseases, and first and second place prizes will be awarded in each category. In addition to grant funding, award recipients will receive travel expenses and registration fees for the annual ARVO meeting.
The award, formerly run by Merck as the Chibret Award, has been granted to more than 50 scientists since its initiation in 1982. Submissions for the first ARVO-AFER/Merck IORA have now closed, and the winners will be announced at the ARVO 2009 annual meeting, to be held on May 3–7 in Fort Lauderdale, US. The application process for the 2011 award will begin in 2010.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Evaluating the clinical performance of ZEISS AT ELANA and the new ’ELISA’* approach
July 30th 2025In this insightful analysis, Dr. Joong Hun Kim presents real-world clinical outcomes with bilateral implantation of ZEISS AT ELANA 841P. Dr. Kim recommends AT ELANA® 841P as an excellent option for patients undergoing cataract surgery as its fully trifocal optical design translates into a full range of vision. He also introduces the so-called ‘ELISA’ approach for patients requiring astigmatic correction in one eye only, combining AT ELANA 841P and ZEISS AT LISA tri toric 939MP. Early objective and subjective clinical data from this novel approach reveal promising visual outcomes and high patient satisfaction
